Journal
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 27, Issue 11, Pages 627-629Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mph.0000188631.41510.23
Keywords
chemotherapy-induced neutropenia; neutropenia; pegfilgrastim; children; cancer
Categories
Ask authors/readers for more resources
Chemotherapy-induced neutropenia is a major dose-limiting side effect of intensive chemotherapy in cancer patients. Recently, pegfilgrastim (a product with a long half-life, resulting in once-per-cycle dosage) was introduced to prevent neutropenia in adults. The authors report 32 episodes of pegfilgrastim use in seven pediatric cancer patients to diminish chemotherapy-induced neutropenia. Feasibility was assessed by adherence to treatment protocol and safety was assessed by adverse effects. There were only two treatment delays (6%) due to neutropenia. No short-term adverse effects were recorded. The use of pegfilgrastim is feasible in pediatric cancer patients, without short-term adverse effects or major treatment delay due to neutropenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available